|
gptkbp:instanceOf
|
gptkb:company
|
|
gptkbp:CEO
|
gptkb:Ge_Li
|
|
gptkbp:country
|
gptkb:China
|
|
gptkbp:founded
|
2000
|
|
gptkbp:founder
|
gptkb:Ge_Li
|
|
gptkbp:headquartersLocation
|
gptkb:Shanghai,_China
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
WuXi AppTec
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:languageOfWork
|
gptkb:Chinese
English
|
|
gptkbp:listedOn
|
gptkb:Fortune_China_500
|
|
gptkbp:notableClient
|
pharmaceutical companies
biotech companies
medical device companies
|
|
gptkbp:notableProject
|
COVID-19 vaccine development support
|
|
gptkbp:numberOfEmployees
|
~36,000
|
|
gptkbp:parentCompany
|
gptkb:WuXi_PharmaTech_(Cayman)_Inc.
|
|
gptkbp:revenue
|
~RMB 40 billion (2023)
|
|
gptkbp:servesArea
|
global
|
|
gptkbp:services
|
contract research
manufacturing
laboratory testing
contract development
|
|
gptkbp:stockExchange
|
gptkb:Hong_Kong_Stock_Exchange
gptkb:Shanghai_Stock_Exchange
|
|
gptkbp:stockSymbol
|
2359
603259
|
|
gptkbp:subsidiary
|
gptkb:WuXi_Biologics
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
https://www.wuxiapptec.com/
|
|
gptkbp:bfsParent
|
gptkb:Juno_Therapeutics
|
|
gptkbp:bfsLayer
|
5
|